\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Gamma Interferon Assay for Cellular Immune Response in Cattle Vaccinated With FMD Vaccine Adjuvanted with Different Montanide Oils}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2015-01-15 (revised: 15 January 2015)} \def\TheID{\makeatother } \def\TheDate{2015-01-15} \title{Gamma Interferon Assay for Cellular Immune Response in Cattle Vaccinated With FMD Vaccine Adjuvanted with Different Montanide Oils} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Ehab EL-Sayed Ibrahim} \affil[1]{ Veterinary serum and vaccine research Institute, Cairo, Egypt} \renewcommand\Authands{ and } \date{\small \em Received: 16 December 2014 Accepted: 5 January 2015 Published: 15 January 2015} \maketitle \begin{abstract} Cell-mediated immunity is critical for the prevention and control of Foot and Mouth Disease (FMD). Despite significant advancements in modern vaccinology, inactivated whole virus vaccines for FMD remain the mainstay for prophylactic and emergency uses. Emergency vaccination as part of the control strategies against foot-and-mouth disease virus (FMDV) has the potential to limit virus spread and reduce large-scale culling. Many efforts are currently devoted to improve the immune responses and protective efficacy of these vaccines. Adjuvants, which are often used to potentiate immune responses, provide an excellent mean to improve the efficacy of FMD vaccines.Aim: To evaluate three oil adjuvants namely: Montanide ISA-206, ISA-201 and ISA-61 for adjuvant potential in inactivated FMD vaccine by determination of the produced amounts of interferon-gamma (IFN-gamma) in cattle vaccinated with FMD trivalent vaccine adjuvanted with different Montanide oils using interferon-gamma Assay for evaluation of FMD virus-specific cell-mediated immunity. \end{abstract} \keywords{} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{I. Introduction}]{I. Introduction}\par oot-and-mouth disease virus (FMDV) causes footand-mouth disease (FMD), a contagious and fatal disease in cloven-hoofed animals, characterized by vesicles in the mouth, tongue, hoofs, and nipples and increase in body temperature and appetite loss \hyperref[b18]{Depa et al., (2012)}. the natural route of infection is via the upper respiratory tract or through ingestion of the virus. Initial virus replication usually occurs in the pharyngeal epithelium resulting in primary vesicles \hyperref[b1]{Alexandersen and Mowat (2005)}. Fever and viraemia can occur within 1-2 days resulting in virus excretion from the respiratory tract, faeces, urine, saliva, milk and semen. Virus entering the blood disseminates to various predilection sites such as the mouth and nose, hooves and also sometimes teats and udder, in which secondary vesicles occur, and from which further virus is released \hyperref[b28]{Grubman (2005)} and Diaz-San et al., {\ref (2009)}. The progress in FMD vaccine production was primarily directed towards safety of the vaccine, purity of the antigen, selection of proper adjuvant and endurance of immunity Osama {\ref (1992)}. Adjuvants, also can prolong the immune response and stimulate specific components of the immune response either humoral or cell mediated immunity \hyperref[b35]{Lombard et al., (2007)} and \hyperref[b6]{Cao (2014)}. Currently, the double oil emulsion vaccines are preferred for FMD prevention as they can be used to protect all susceptible species, particularly dur-ing an outbreak situation \hyperref[b12]{Cox and Barnett (2009)}. Also, the oil adjuvant vaccines generate higher and long lasting immune responses, and show less inter-ference from maternal antibodies than the aqueous vaccines \hyperref[b45]{Selim et al., (2010)}. In particular, the Montanide TM ISA series of oil-adjuvants (SEPPIC France) have shown superior efficacy for inactivated FMD vaccines in different susceptible animal species \hyperref[b33]{Iyer et al., (2000)}. Recently, SEPPIC has developed a new adjuvants (Montanide ISA-201 and Montanide ISA-61) and claim that those adjuvants induce better immune responses (particularly CMI responses) Seppic. Montanide ISA 201 VG-ready to use oil adjuvant for veterinary vaccines and Sébastien et al., {\ref (2013)}. The ability to stimulate cell-mediated immunity (CMI) and conse-quent inhibition of subclinical infection in ruminants or otherwise induction of sterile immunity is usually insufficient \hyperref[b37]{Moonen et al., (2004)} Interferons belong to cytokines. They are glycoproteins with multifaceted signal effects on cellular functions among which the antiviral effects belong to the early and non-specific defense mechanisms of organisms against infections \hyperref[b49]{Vilcek and Sen (1996)}.\par Interferons (IFNs) are the first line of the host innate immune defense against important, derives from its immunostimulatory and immunomodulatory effects \hyperref[b42]{Samuel (2001)} and \hyperref[b17]{Delcenserie et al., (2008)}. The assay system has proven to be a rapid, sensitive and inexpensive method for measuring antigen specific cellmediated reactivity when compared with the more traditional lymphocyte proliferation assay. The IFNgamma assay is the first in-vitro cellular assay to be used as a routine diagnostic test in veterinary medicine \hyperref[b41]{Rothel et al., (1992)}. The production of interferongamma by stimulated helper T lymphocytes regulates production of immunoglobulin in vaccinated animals \hyperref[b27]{Green et al., (2015)}. IFN-gamma is a modulator of T-cell growth and functional differentiation. It is a growthpromoting factor for T-lymphocytes and potentiates the response of these cells to mitogens or growth factors. The production of IFN-gamma or IL-4 by subsets of helper T lymphocytes reciprocally regulates production of lgG2a and IgG1.The minimum detectable dose of IFN-gamma is typically less than 5 pg/ml \hyperref[b13]{Cubillos et al., (2008)} and \hyperref[b5]{Bucafusco et al., (2015)}, while the protective level is more than 38\% Sample to Positive (SP \%) \hyperref[b29]{Gurung et al., (2014)}.\par It has been suggested that cell-mediated immunity may be involved in the clearance viral infection so the importance of Interferon-Gamma (IFN-gamma) in the immune system stems in part from its ability to inhibit viral replication directly, but, most of persistent virus \hyperref[b32]{Ilott et al., (1997)} and \hyperref[b11]{Childerstone et al., (1999)} and it has been hypothesised that the initiation of FMDV persistence is correlated with the amount of interferon produced in the cells \hyperref[b40]{Phillips and Dinter (1963)}. FMDV strains modified by passage in alternate hosts or repeated passage in cell cultures have reduced virulence in cattle and, in contrast to more virulent wildvirus, will induce the production of interferon \hyperref[b54]{Zhang et al., (2014)} with a correlation between lack of virulence in cattle and increased IFN production \hyperref[b0]{Alexandersen et al.,(2002)}.\par The present work aims to evaluate the FMD virus-specific cell-mediated immunity in cattle vaccinated with FMD vaccine adjuvanted with different Montanide oils using interferon-gamma Assay, in order to determine to any extent FMD trivalent vaccine is able to elicit a sterile immunity. \section[{II. Material and Methods}]{II. Material and Methods} \section[{a) Cell and virus}]{a) Cell and virus}\par Baby Hamster Kidney cell line (BHK21) Clone 13 maintained in FMD Department, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo according to the technique described by \hyperref[b36]{Macpherson and Stocher (1962)} \hyperref[b34]{Killington et al., (1996)}. The viral suspension was concentrated at 25,000 rpm, for 5 hours at 4? in a highspeed centrifuge (Avanti J25, Beckman Coulter, and Fullerton, CA, USA), the virus in the bottom was removed and polled. The virus was further concentrated in ultracentrifuge 35,000 rpm/min, 3 hours at 4?, the viral pelted polled and aliquots of the concentrated virus preserved at -80?. \section[{c) FMD viruses inactivation}]{c) FMD viruses inactivation}\par The concentrated virus stock completely inactivated using Binary Ethyleneimine (BEI) according to \hyperref[b2]{Bahnemann (1975)}, 1\%M BEI in 0.2N NaOH was added to the virus suspension to give final concentration of 0.001M of BEI. The virus and BEI mixture were mixed well and the pH adjusted to 8.0 by sodium bicarbonate. The virus was placed in the incubator at 37 o C for 24 hours for inactivation to occur. Sodium thiosulphate was added to give a final concentration of 2\% to neutralize the BEI action. The killed vaccine kept at -80?, to use in preparation of vaccine formulation with different Montanide Oil adjuvants (ISA 206,201 and 61) for animal immunization according to FAO. (2012). \section[{d) Montanide ISA 206}]{d) Montanide ISA 206}\par This is a mineral oil based adjuvant which has been developed for the manufacture of Water-in-Oil-in-Water (W/O/W) emulsions mixed with antigen 50\% w/w. It was obtained from Seppic, Paris, France. \section[{e) Montanide ISA 201}]{e) Montanide ISA 201}\par This is a mineral oil based adjuvant that has been developed for the manufacture of Water-in-Oil-in-Water (W/O/W) emulsions mixed with antigen 50\% w/w. It was obtained from Seppic, Paris, France. \section[{f) Montanide ISA 61}]{f) Montanide ISA 61}\par This is a mineral oil based adjuvant that has been developed for the manufacture of water-in-oil (W/O) emulsions mixed with antigen 60\% w/w. It was obtained from Seppic, Paris, France. \section[{g) Trivalent FMD vaccines preparation i. FMD oil adjuvanted vaccine formulated with Montanide ISA 206}]{g) Trivalent FMD vaccines preparation i. FMD oil adjuvanted vaccine formulated with Montanide ISA 206}\par Formulation with oil phase carried out according to the method described by Wael et al., {\ref (2014)}, where the oil phase consisted of Montnide ISA 206 mixed with the inactivated viruses as equal parts of an aqueous and oil phase (50\% w/ w) and mixed thoroughly. \section[{ii. FMD oil adjuvanted vaccine formulated with}]{ii. FMD oil adjuvanted vaccine formulated with}\par Montanide ISA 201 Formulation with oil phase carried out according to the method described by \hyperref[b15]{Dar et al., (2013)} and {\ref Ehab et al., (2015)} where the oil phase consisted of Montnide ISA 201 mixed with the inactivated viruses as equal parts of an aqueous and oil phase (50\% w/ w) and mixed thoroughly. \section[{iii. FMD oil adjuvanted vaccine formulated with}]{iii. FMD oil adjuvanted vaccine formulated with}\par Montanide ISA 61 Formulation with oil phase carried out according to the method described by \hyperref[b29]{Gurung et al., (2014)} where the oil phase consisted of Montnide ISA 61 mixed with the inactivated viruses as 60\% of an aqueous and oil phase (60\% w/w) and mixed thoroughly. \section[{h) Animal groups}]{h) Animal groups}\par .Twelve calves (local breed) were clinically healthy and free from antibodies against FMD virus as proved by using SNT and ELISA were used in this study.\par Calves used in experimental vaccination were classified into four groups: \section[{i) Samples collection}]{i) Samples collection}\par Blood samples were collected on 3 rd post vaccination every three days for 2 weeks and later every week up to 10 weeks. Serum samples were collected weekly post vaccination for one month then every 2 weeks post-vaccination till the end of experiment. The immune response was evaluated through the detection of INF-gamma and humoral immune level using Bovine IFN-gamma ELISA assays, SNT and ELISA.\par i. Detection of interferon gamma (IFN-gamma) using Bovine IFN-gamma ELISA kits It was applied according to \hyperref[b4]{Barnett et al., (2004)}. The cytokine IFN-gamma was measured in plasma samples from all cattle groups at various time points before and following vaccination using Bovine IFN-? ELISA kit (Mabtech-Sweden -code/3115-1H-20). High protein binding ELISA plates were coated with mAb bIFN-?-1 diluted to 2µg/ml in PBS, PH 7.4, by adding 100 µl/well incubated overnight 4-8?C according to the manual technique. The plates were washed with PBS (200µl/well) before blocking with PBS containing 1\% bovine serum albumin for 30 min at room temperature. Blocked plates then were washed five times with PBS containing 0.05\% Tween 20(Incubation buffer).\par Bovine IFN-gamma was prepared standard by reconstituting content of vial in 1ml PBS to give concentration of 0.5µg/ml and leaved at room temperature for 15 minutes, then vortex the tube and spin down and use immediately. Samples or standards diluted in incubation buffer added as 100µl/well and incubated for 2 hours at room temperature, then washed as before. Then 100µl/well of mAb PAN-biotin at 0.1g/ml in incubation buffer was added, incubated for 1 hour at room temperature and then washed as washing step. Then 100µl/well of Streptavidin-Horse Radish Peroxidase (Streptavidin-HRP) diluted 1:1000 in incubation buffer was added and incubated at room temperature for 1 hour.\par Appropriate substrate solution was added as 100µl/well. Finally measured the optical density in an ELISA reader after suitable developing time, absorbance values were read at 492 nm and the results were calculated according to kits typical data. Optical density values were normalized across plates using the following calculation: ii \section[{. Serum neutralization test (SNT)}]{. Serum neutralization test (SNT)}\par The test was performed by the microtechnique as described by \hyperref[b26]{Ferreira (1976)} in flat bottom tissue culture microtitre plates.\par iii. Enzyme linked immunosrobent assay (ELISA) It was carried out according to the method described by \hyperref[b50]{Voller et al., (1976)}.\par Serum samples were examined for FMD viral specific IgG antibodies using in-house developed ELISA assay. \section[{III. Results}]{III. Results}\par Table \hyperref[b0]{(1)} IFN-gamma for Montanide ISA 201 group (Group B) detected at 3 rd day following vaccination. Mean IFN-gamma cons. was (200pg/ml), Optical density (O.D.) was 0.765 and SP\% was (40\%). The highest level was at 14 Th day, with a cons. of (500pg/ml) and O.D. of 1.743 and SP\% (93\%). It was at protective level (>38\%) till 42 days post vaccination. Tables \hyperref[b2]{(3)} IFN-gamma for Montanide ISA 61 group (Group C) detected at 3 rd day following vaccination. Mean IFNgamma cons. was (250pg/ml), Optical density (O.D.) was as 0.881 and SP\% was (46\%). The highest level was at 14 Th day, with a cons. of (800pg/ml) and O.D. of 1.847 and SP\% (97.5\%). It was at protective level (>38\%) till 56 days post vaccination. Tables \hyperref[tab_7]{(4)} IFN-gamma level of was undetectable in plasma of control unvaccinated group (Group D). \section[{b) Evaluation of humeral immune response in calves vaccinated with FMD vaccines using SNT against FMDV serotypes (O,A\&SAT2)}]{b) Evaluation of humeral immune response in calves vaccinated with FMD vaccines using SNT against FMDV serotypes (O,A\&SAT2)}\par The humeral immune response of calves vaccinated with trivalent FMD vaccines(formulated with Montanide oil ISA 206,201 and 61) using SNT for FMD virus showed that protective neutralizing serum antibody titer for Montanide ISA 206 started at the 2 nd week post vaccination with average antibody titer of (1.5-1.6 \&1.5 log 10 ) for (O, A \& SAT2 ) respectively. The obtained antibody titer reached to the peak level at 10 th week post vaccination with average titers of (2.4 -2.7 \&2.6 log 10 ). The protective neutralizing serum antibody titer for Montanide ISA 201 started at the 1 st week post vaccination with average antibody titer of (1.5-1.6\&1.5 log 10 ) for (O, A\&SAT2) respectively. The obtained antibody titer reached to the peak level at 10 th week post vaccination with average titers of (3.05-3.1 \&3.05 log 10 ).The protective neutralizing serum antibody titer for Montanide ISA 61started at the 1 st week post vaccination with average antibody titer of (1.7, 1.8 \&1.7 log 10 ) for (O, A\&SAT2) respectively. The obtained antibody titer reached to the peak level at 10 th week post vaccination with average titers of (3.1-3.4\&3.1 log 10 ). Tables \hyperref[b4]{(5)} Table \hyperref[b4]{(5)} \par * = Antibody titers expressed as log 10 serum neutralizing antibody titer.\par Protective level {\ref (1.5)} \section[{c) Evaluation of humeral immune response in calves vaccinated with FMD vaccines using ELISA against FMDV. serotypes (O,A\&SAT2)}]{c) Evaluation of humeral immune response in calves vaccinated with FMD vaccines using ELISA against FMDV. serotypes (O,A\&SAT2)}\par The protective antibody titer for FMD vaccine formulated with Montanide ISA 206 started at the 2 st week post vaccination with average antibody titer of (1.40 -1.50\& 1.50 log 10 ) for O,A \& SAT2 respectively . The obtained antibody titer reached to the peak level at 10 th week post vaccination with average titers of (2.90 -2.92 \& 2.92log 10 ) for (O, A\&SAT2) respectively.\par The protective antibody titer for Montanide ISA 201 started at the 1 st week post vaccination with average antibody titer of (1.93 -1.95 \&1.93 log 10 ). The obtained antibody titer reached to the peak level at 10 th week post vaccination with average titers of (3.12-3.15 \&3.13 log10). The protective neutralizing serum antibody titer for Montanide ISA 61 started at the 2 nd week post vaccination with average antibody titer of (1.97-1.99 \& 1.96 log 10 ). The obtained antibody titer reached to the peak level at 10 th week post vaccination with average titers of (3.32 -3.34 \&3.33 log10).Table \hyperref[b5]{(6)}.\par Table \hyperref[b5]{(6)} : Antibody titers of calves vaccinated with inactivated trivalent FMD vaccine using ELISA against FMDV serotype (O, A and SAT2). \section[{IV. Discussion}]{IV. Discussion}\par The first use of an oil adjuvant inactivated FMD vaccine was stated by Cunliffe and Graves {\ref (1963)}. Such vaccine was found to induce higher immune levels and protection in vaccinated cattle than that induced by the conventional aluminum hydroxide vaccines. So it could be considered an important tool in the control programs of FMD \hyperref[b3]{Bahnemann and Mesquita (1987)} and \hyperref[b33]{Iyer et al., (2000)}. An adjuvant may act in one or more of five ways, based on current knowledge; namely, immunemodulation, presentation, induction of CD8+cytotoxic Tlymphocyte (CTL) responses, targeting, and depot generation. Addition to that adjuvant plays an important role in production of different lympho-kines such as various interleukins and INF-gamma according to \hyperref[b4]{Barnett et al., (2004)} and \hyperref[b23]{Ebeid et al., (2011)}. The innate immune response induced by a viral infection in the upper respiratory tract, the macrophages present in the respiratory tract produce interferons (IFNs) upon stimulation of pattern recognizing surface receptors, causing alterations in local vascular walls, and providing recruitment and activating stimuli to antigen presenting cells and phagocytes \hyperref[b52]{Wilkins and Gale (2010)}. IFNs are also known as viral IFNs and secreted by virus infected cells with the function of blocking spread of virus to uninfected cells and have an important role in the host response to {\ref FMDV Summerfield et al., (2009)} and that the ability of the virus to induce an IFN response may be related to the pathogenicity of different isolates of FMDV Santos et al., {\ref (2006)} and \hyperref[b47]{Stenfeldt et al., (2011)}. To better characterize the immune response to FMD vaccines and to search for early markers predictive of induction of immune memory; must analyze the kinetics and magnitude of the antibody and cell-mediated immune responses to FMD vaccinesand further characterization of the antigen-specific CD4 + T-cell response better to be attempt by measuring IFN-gamma production {\ref Carr et al., (2013)}.\par So, this study was performed for evaluation of FMD virus-specific cell-mediated immunity in cattle vaccinated with FMD vaccine adjuvanted with different Montanide oils using interferon-gamma Assay, in order to determine to any extent FMD trivalent vaccine is able to elicit a sterile immunity. {\ref 2014}) who observed that vaccine formulated with ISA 61 showed the highest specific IFN-gamma responses among the different ISA oil formulations, which can be observed at 9 weeks post vaccination. The results also showed that great variation was observed between the vaccinated animal groups in INF-gamma production level depending on the adjuvant. From previous results, the quantity of IFN-gamma produced was significantly the highest in group (C) compared to the other groups from day 3 till day 63 post-vaccination .Also, the quantity of IFN-? produced in the plasma samples from vaccinated animals was significantly higher than the quantity produced in the samples from the unvaccinated control animals. From tables (5and 6) the results revealed that SNT and ELISA titers for different oil FMD vaccines agreed with \hyperref[b15]{Dar et al., (2013)} who showed that Montanide ISA-201 adjuvanted vaccine induced earlier and higher neutralizing antibody responses as compared to the two other oil adjuvants, also were supported by \hyperref[b39]{Parida et al., (2006)} who recorded that IFN-production assay could be used to support the established serological assays to confirm infection in a previously vaccinated herd. Our results also go in hand with the results obtained were consistent with the statement of \hyperref[b31]{Hamblin et al., (1986)} who explained that the SNT measures those antibodies which neutralize the infectivity of FMD virion, while ELISA probably measure all classes of antibodies even those produced against incomplete and non-infectious virus.\par The obtained results were in agreement with \hyperref[b39]{Parida et al., (2006)} and \hyperref[b4]{Barnett et al., (2004)} who showed that in a vaccine IFN-gamma response could be a useful indicator of the ability of a FMD vaccine to elicit a so-called sterile immunity in which subclinical infection is prevented. This early IFN-gamma production probably comes from NK cells activated by macrophage derived cytokines as part of the innate immune response.\par Our results also were supported by \hyperref[b53]{Wu et al., (2003)} and Diaz-San et al., (2010) who suggested that there is a complex interplay between IFN-induced immunomodulatory in protection of animals against FMDV.\par Finally, conclusion from the obtained results through the present study it could be concluded that, all of the prepared vaccines were capable of stimulating a systemic gamma interferon response. Montanide ISA-61 adjuvanted vaccine induced early response, high cellular and humeral immunity and produced higher IFNgamma as compared to the two other adjuvants, while no systemic IFN-gamma was detected in plasma samples from the unvaccinated cattle.\begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-2.png} \caption{\label{fig_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-3.png} \caption{\label{fig_1}}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.18021201413427562\textwidth}P{0.11113074204946997\textwidth}P{0.36643109540636043\textwidth}P{0.192226148409894\textwidth}} \multicolumn{2}{l}{Standard Bovine IFN-gamma Concentration (pg/ml)}\tabcellsep O.D. at 492 nm\tabcellsep Mean O.D. at 492 nm\\ 1\tabcellsep 1000.0\tabcellsep 1.983 -1.977\tabcellsep 1.980\\ 2\tabcellsep 500.0\tabcellsep 1.701 -1.790\tabcellsep 1.746\\ 3\tabcellsep 250.0\tabcellsep 0.881 -0.876\tabcellsep 0.879\\ 4\tabcellsep 125.0\tabcellsep 0.462 -0.485\tabcellsep 0.479\\ 5\tabcellsep 62.5\tabcellsep 0.252 -0.258\tabcellsep 0.255\\ 6\tabcellsep 31.3\tabcellsep 0.144 -0.149\tabcellsep 0.147\\ 7\tabcellsep 15.6\tabcellsep 0.093 -0.096\tabcellsep 0.095\\ 8\tabcellsep 7.8\tabcellsep 0.067 -0.067\tabcellsep 0.067\\ Blank\tabcellsep 0\tabcellsep 0.031 -0.028\tabcellsep 0.030\end{longtable} \par {\small\itshape [Note: Chart\hyperref[b0]{(1)} : Standard curve for typical data using Bovine IFN-gamma ELISA Kits]} \caption{\label{tab_1}:}\end{figure} \begin{figure}[htbp] \noindent\textbf{(} \par \begin{longtable}{P{0.022266514806378132\textwidth}P{0.1490888382687927\textwidth}P{0.13940774487471527\textwidth}P{0.15392938496583145\textwidth}P{0.13553530751708429\textwidth}P{0.13747152619589978\textwidth}P{0.11230068337129841\textwidth}} \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Vaccinated cattle}\tabcellsep \tabcellsep Mean\\ Days\tabcellsep IFN-gamma\tabcellsep A1\tabcellsep A2\tabcellsep A3\tabcellsep Mean\tabcellsep Control group\\ \tabcellsep *cons.\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\\ 0\tabcellsep O.D\tabcellsep 0.031\tabcellsep 0.030\tabcellsep 0.029\tabcellsep 0.030\tabcellsep 0.030\\ \tabcellsep **SP\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\\ 3\tabcellsep ?cons.\tabcellsep 125.0\tabcellsep 125.0\tabcellsep 62.5\tabcellsep 100\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.462\tabcellsep 0.462\tabcellsep 0.258\tabcellsep 0.394\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 23\%\tabcellsep 23\%\tabcellsep 12\%\tabcellsep 19.5\%\tabcellsep 0\%\\ 7\tabcellsep ?cons.\tabcellsep 200.0\tabcellsep 200\tabcellsep 200\tabcellsep 200\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.761\tabcellsep 0.765\tabcellsep 0.763\tabcellsep 0.763\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 40\%\tabcellsep 40\%\tabcellsep 40\%\tabcellsep 40\%\tabcellsep 0\%\\ 10\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 14\tabcellsep ?cons.\tabcellsep 450\tabcellsep 450\tabcellsep 450\tabcellsep 450\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.572\tabcellsep 1.572\tabcellsep 1.572\tabcellsep 1.572\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 84\%\tabcellsep 84\%\tabcellsep 84\%\tabcellsep 84\%\tabcellsep 0\%\\ 21\tabcellsep ?cons.\tabcellsep 450\tabcellsep 450\tabcellsep 450\tabcellsep 450\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.572\tabcellsep 1.572\tabcellsep 1.572\tabcellsep 1.572\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 84\%\tabcellsep 84\%\tabcellsep 84\%\tabcellsep 84\%\tabcellsep 0\%\\ 28\tabcellsep ?cons.\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.402\tabcellsep 1.400\tabcellsep 1.401\tabcellsep 1.400\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 0\%\\ 35\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 42\tabcellsep ?cons.\tabcellsep 125.0\tabcellsep 125.0\tabcellsep 62.5\tabcellsep 100\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.462\tabcellsep 0.462\tabcellsep 0.258\tabcellsep 0.394\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 23\%\tabcellsep 23\%\tabcellsep 12\%\tabcellsep 20\%\tabcellsep 0\%\\ 49\tabcellsep ?cons.\tabcellsep 100\tabcellsep 100\tabcellsep 100\tabcellsep 100\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.396\tabcellsep 0.392\tabcellsep 0.394\tabcellsep 0.394\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 19.5\%\tabcellsep 19.5\%\tabcellsep 19.5\%\tabcellsep 19.5\%\tabcellsep 0\%\\ 56\tabcellsep ?cons.\tabcellsep 62.5\tabcellsep 62.5\tabcellsep 62.5\tabcellsep 62.5\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.258\tabcellsep 0.254\tabcellsep 0.256\tabcellsep 0.256\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 12\%\tabcellsep 12\%\tabcellsep 12\%\tabcellsep 12\%\tabcellsep 0\%\end{longtable} \par \caption{\label{tab_2}Table ( 2}\end{figure} \begin{figure}[htbp] \noindent\textbf{(} \par \begin{longtable}{P{0.09944048830111903\textwidth}P{0.13316378433367243\textwidth}P{0.12884028484231944\textwidth}P{0.13835198372329605\textwidth}P{0.12538148524923703\textwidth}P{0.12538148524923703\textwidth}P{0.09944048830111903\textwidth}} \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Vaccinated cattle}\tabcellsep \tabcellsep Mean\\ Days *\tabcellsep IFN-gamma\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Control\\ \tabcellsep \tabcellsep A1\tabcellsep A2\tabcellsep A3\tabcellsep Mean\tabcellsep group\\ \tabcellsep *cons.\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\\ 0\tabcellsep O.D\tabcellsep 0.031\tabcellsep 0.030\tabcellsep 0.029\tabcellsep 0.030\tabcellsep 0.030\\ \tabcellsep **SP\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\\ 3\tabcellsep ?cons.\tabcellsep 200.0\tabcellsep 200\tabcellsep 200\tabcellsep 200\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.764\tabcellsep 0.765\tabcellsep 0.766\tabcellsep 0.765\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 40\%\tabcellsep 40\%\tabcellsep 40\%\tabcellsep 40\%\tabcellsep 0\%\\ 7\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 10\tabcellsep ?cons.\tabcellsep 500.0\tabcellsep 500\tabcellsep 500\tabcellsep 500\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.745\tabcellsep 1.742\tabcellsep 1.742\tabcellsep 1.743\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 93\%\tabcellsep 93\%\tabcellsep 93\%\tabcellsep 93\%\tabcellsep 0\%\\ 14\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 21\tabcellsep ?cons.\tabcellsep 500.0\tabcellsep 450\tabcellsep 500.0\tabcellsep 650\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.742\tabcellsep 1.572\tabcellsep 1.742\tabcellsep 1.685\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 92\%\tabcellsep 83\%\tabcellsep 92\%\tabcellsep 89\%\tabcellsep 0\%\\ 28\tabcellsep ?cons.\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.402\tabcellsep 1.402\tabcellsep 1.402\tabcellsep 1.402\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 0\%\\ 35\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 42\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 49\tabcellsep ?cons.\tabcellsep 125.0\tabcellsep 125.0\tabcellsep 125.0\tabcellsep 125.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.460\tabcellsep 0.462\tabcellsep 0.464\tabcellsep 0.462\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 23\%\tabcellsep 23\%\tabcellsep 23\%\tabcellsep 23\%\tabcellsep 0\%\\ 56\tabcellsep ?cons.\tabcellsep 100\tabcellsep 100\tabcellsep 100\tabcellsep 100\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.392\tabcellsep 0.394\tabcellsep 0.396\tabcellsep 0.394\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 19.5\%\tabcellsep 19.5\%\tabcellsep 19.5\%\tabcellsep 19.5\%\tabcellsep 0\%\\ \multicolumn{2}{l}{*IFN-gamma cons. (pg/ml)}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ O.D. at492 nm\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{2}{l}{** Sample-to positive \%}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{2}{l}{SP\% protection cutoff > 38\%}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_3}Table ( 3}\end{figure} \begin{figure}[htbp] \noindent\textbf{(} \par \begin{longtable}{P{0.10056584362139917\textwidth}P{0.1346707818930041\textwidth}P{0.12767489711934157\textwidth}P{0.13554526748971193\textwidth}P{0.1259259259259259\textwidth}P{0.1250514403292181\textwidth}P{0.10056584362139917\textwidth}} \tabcellsep \tabcellsep \tabcellsep \multicolumn{2}{l}{Vaccinated cattle}\tabcellsep \tabcellsep Mean\\ Days *\tabcellsep IFN-gamma\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Control\\ \tabcellsep \tabcellsep A1\tabcellsep A2\tabcellsep A3\tabcellsep Mean\tabcellsep group\\ \tabcellsep *cons.\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\tabcellsep 0\\ 0\tabcellsep O.D\tabcellsep 0.030\tabcellsep 0.030\tabcellsep 0.030\tabcellsep 0.030\tabcellsep 0.030\\ \tabcellsep **SP\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\tabcellsep 0\%\\ 3\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 7\tabcellsep ?cons.\tabcellsep 500.0\tabcellsep 500\tabcellsep 500\tabcellsep 500\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.745\tabcellsep 1.745\tabcellsep 1.745\tabcellsep 1.745\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 93\%\tabcellsep 93\%\tabcellsep 93\%\tabcellsep 93\%\tabcellsep 0\%\\ 10\tabcellsep ?cons.\tabcellsep 1000\tabcellsep 650\tabcellsep 800\tabcellsep 800\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.981\tabcellsep 1.673\tabcellsep 1.887\tabcellsep 1.847\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 105\%\tabcellsep 88\%\tabcellsep 100\%\tabcellsep 97.5\%\tabcellsep 0\%\\ 14\tabcellsep ?cons.\tabcellsep 800\tabcellsep 800\tabcellsep 500.0\tabcellsep 800\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.887\tabcellsep 1.887\tabcellsep 1.750\tabcellsep 1.841\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 100\%\tabcellsep 100\%\tabcellsep 92\%\tabcellsep 97.5\%\tabcellsep 0\%\\ 21\tabcellsep ?cons.\tabcellsep 500.0\tabcellsep 450\tabcellsep 500.0\tabcellsep 650\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.742\tabcellsep 1.572\tabcellsep 1.742\tabcellsep 1.685\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 92\%\tabcellsep 83\%\tabcellsep 92\%\tabcellsep 89\%\tabcellsep 0\%\\ 28\tabcellsep ?cons.\tabcellsep 500.0\tabcellsep 450\tabcellsep 500.0\tabcellsep 650\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.742\tabcellsep 1.572\tabcellsep 1.742\tabcellsep 1.685\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 92\%\tabcellsep 83\%\tabcellsep 92\%\tabcellsep 89\%\tabcellsep 0\%\\ 35\tabcellsep ?cons.\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.402\tabcellsep 1.400\tabcellsep 1.401\tabcellsep 1.400\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 0\%\\ 42\tabcellsep ?cons.\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 400\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 1.402\tabcellsep 1.400\tabcellsep 1.401\tabcellsep 1.400\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 74\%\tabcellsep 0\%\\ 49\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ 56\tabcellsep ?cons.\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 250.0\tabcellsep 0\\ \tabcellsep O.D\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.881\tabcellsep 0.030\\ \tabcellsep SP\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 46\%\tabcellsep 0\%\\ \multicolumn{2}{l}{*IFN-gamma cons. (pg/ml)}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ O.D. at492 nm\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\ \multicolumn{3}{l}{** Sample-to positive \%SP\% protection cutoff > 38\%}\tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_4}Table ( 4}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.14311224489795918\textwidth}P{0.06071428571428571\textwidth}P{0.07806122448979592\textwidth}P{0.11420068027210885\textwidth}P{0.05493197278911564\textwidth}P{0.07661564625850341\textwidth}P{0.05926870748299319\textwidth}P{0.056377551020408166\textwidth}P{0.07517006802721088\textwidth}P{0.06071428571428571\textwidth}P{0.07083333333333333\textwidth}} \tabcellsep \tabcellsep \tabcellsep \multicolumn{5}{l}{SNT titers of vaccinated animal groups}\tabcellsep \tabcellsep \tabcellsep Control group\\ Time\tabcellsep \tabcellsep Group A\tabcellsep \tabcellsep \tabcellsep Group B\tabcellsep \tabcellsep \tabcellsep Group C\tabcellsep \tabcellsep \\ post vaccination\tabcellsep \tabcellsep (ISA 206)\tabcellsep \tabcellsep \tabcellsep (ISA 201)\tabcellsep \tabcellsep \tabcellsep (ISA 61)\tabcellsep \tabcellsep \\ \tabcellsep O\tabcellsep A\tabcellsep SAT2\tabcellsep O\tabcellsep A\tabcellsep SAT2\tabcellsep O\tabcellsep A\tabcellsep SAT2\tabcellsep \\ 0\tabcellsep 0.15*\tabcellsep 0.12\tabcellsep 0.12\tabcellsep 0.3\tabcellsep 0.3\tabcellsep 0.3\tabcellsep 0.3\tabcellsep 0.3\tabcellsep 0.3\tabcellsep 0.3\\ 1 week\tabcellsep 0.9\tabcellsep 1.2\tabcellsep 0.9\tabcellsep 1.5\tabcellsep 1.6\tabcellsep 1.5\tabcellsep 1.7\tabcellsep 1.8\tabcellsep 1.7\tabcellsep 0.3\\ 2 week\tabcellsep 1.5\tabcellsep 1.6\tabcellsep 1.5\tabcellsep 1.7\tabcellsep 1.8\tabcellsep 1.7\tabcellsep 1.8\tabcellsep 2.1\tabcellsep 1.8\tabcellsep 0.3\\ 3 week\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 1.8\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 0.3\\ 4 week\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.7\tabcellsep 2.7\tabcellsep 0.6\\ 6 week\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.9\tabcellsep 2.7\tabcellsep 0.9\\ 8 week\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.9\tabcellsep 2.7\tabcellsep 3.05\tabcellsep 3.1\tabcellsep 3.05\tabcellsep 0.9\\ 10 week\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.6\tabcellsep 3.05\tabcellsep 3.1\tabcellsep 3.05\tabcellsep 3.1\tabcellsep 3.4\tabcellsep 3.1\tabcellsep 0.9\\ 12 week\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.9\tabcellsep 2.7\tabcellsep 3.05\tabcellsep 3.1\tabcellsep 3.05\tabcellsep 0.6\\ 14 week\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.7\tabcellsep 2.7\tabcellsep 2.7\tabcellsep 2.8\tabcellsep 2.8\tabcellsep 2.8\tabcellsep 0.6\\ 16 week\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.4\tabcellsep 2.7\tabcellsep 2.8\tabcellsep 2.7\tabcellsep 0.6\\ 18 week\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.1\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.4\tabcellsep 2.6\tabcellsep 2.7\tabcellsep 2.6\tabcellsep 0.6\\ 20 week\tabcellsep 1.8\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par \caption{\label{tab_5}:}\end{figure} \begin{figure}[htbp] \noindent\textbf{(} \par \begin{longtable}{P{0.85\textwidth}} 1) and Chart (1) show the typical data\\ using Bovine IFN-gamma ELISA Kits for 8 slandered\\ solutions beside the blank one. Bovine IFN-gamma\\ Concentration (pg/ml) with the respectively O.D. at 492\\ nm.\\ From Tables (2, 3 and 4) no systemic IFN-\\ gamma was detected in plasma samples from the\\ unvaccinated cattle. IFN-gamma for Montanise ISA 206\\ group (Group A) detected at 7 th day following\\ vaccination, that results agreed with Stenfeldt et al.,\\ (2011) who observed that within seven days of\\ vaccination with FMD oil vaccine, IFN-gamma\\ production was observed and supported with Cavalcanti\\ et al., (2012) and Bucafusco et al., (2015) they found\\ that on day 7 both CD4 + and CD8 + T cell populations\\ produced IFN-gamma .The obtained results also in\\ agreement in some points with Habjanec et al., (2008)\\ who stated that ISA206 formulations were less effective\\ in inducing INF-gamma. IFN-gamma for Montanise ISA\\ 201 group (Group B) detected at 3 rd day following\\ vaccination and that results agreed with Dar et al.,\\ (2013) who observed that Montanide ISA-201\\ adjuvanted vaccine induced earlier and higher immune\\ response in vaccinated animals, and supported with\\ Gurung et al., (2014) who reported that vaccine\\ formulation with the antigen and Montanide? ISA 201\\ adjuvant produced strong specific IFN-gamma\\ responses in a high proportion of the vaccinated\\ animals. IFN-gamma for Montanide ISA 201 group\\ (Group B) detected at 3 rd day following vaccination and\\ that results agreed with Dar et al., (2013) who observed\\ that Montanide ISA-201 adjuvanted vaccine induced\\ earlier and higher immune response in vaccinated\\ animals, and supported with Gurung et al., (2014) who\\ reported that vaccine formulation with the antigen\\ and Montanide? ISA 201VG adjuvant produced strong\\ specific IFN-gamma responses in a high proportion of\\ the vaccinated animals. The results also come parallel\\ and in agreement with what obtained by Dong et al.,\\ (2013) who reported that the efficacy of the FMD\\ vaccine emulsified with ISA 201 was better than which\\ with ISA 206. IFN-gamma for Montanide ISA 61 group\\ (Group C) detected at 3 rd day following vaccination and\\ that results agreed with Gurung et al., (\end{longtable} \par \caption{\label{tab_7}Table (}\end{figure} \backmatter \begin{bibitemlist}{1} \bibitem[Carr et al.]{b7}\label{b7} \textit{}, B V Carr , E A Lefevre , M A Windsor , Inghese . \bibitem[Cavalcanti and Brelaz]{b9}\label{b9} \textit{}, Y V Cavalcanti , M C Brelaz . Neves JK, Ferraz. \bibitem[Diaz-San et al.]{b20}\label{b20} \textit{}, Diaz-San , F Segundo , M P Moraes , T De Los Santos , C C Dias , Grubman . \bibitem[Dar et al. ()]{b15}\label{b15} \textit{}, P Dar , R Kalaivanan , N Sied , B Mamo , S Kishore , V V Suryanarayana , G Kondabattula . 2013. \bibitem[Lombard et al. ()]{b35}\label{b35} ‘A brief history of vaccines and vaccination’. M Lombard , P P Pastoret , A M Moulin . \textit{Rev. Sci. Tech} 2007. 26 (1) p. . \bibitem[Hamblin et al. ()]{b31}\label{b31} ‘A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-andmouth disease virus. I. Development and method of ELISA’. C Hamblin , Barnett , R S Hedger . \textit{J Immunol Methods} 1986. 93 (1) p. . \bibitem[Wu et al. ()]{b53}\label{b53} ‘Adenovirus-mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus’. Q Wu , M C Brum , L Caron , M Koste , M J Grubman . \textit{J .Interferon Cytokine Res} 2003. 23 (7) p. . \bibitem[Cao ()]{b6}\label{b6} \textit{Adjuvants for foot-and-mouth disease virus vaccines: recent progress Expert Rev Vaccines}, Y Cao . 2014. 13 p. . \bibitem[Stenfeldt et al. ()]{b47}\label{b47} ‘Analysis of the acute phase responses of serum amyloid A, haptoglobin and Type 1 Interferon in cattle experimentally infected with foot-andmouth disease virus serotype O’. C Stenfeldt , P M Heegaard , A Stockmarr , K Tjornehoj , G J Belsham . \textit{Veterinary Research} 2011. 42 p. 66. \bibitem[Samuel ()]{b42}\label{b42} ‘Antiviral actions of interferons’. C E Samuel . \textit{Clin. Microbiol. Rev} 2001. 14 p. . \bibitem[Alexandersen et al. ()]{b0}\label{b0} ‘Aspects of the persistence of foot-andmouth disease virus in animals--the carrier problem’. S Alexandersen , Z Zhang , A I Donaldson . \textit{Microbes Infect} 2002. 4 p. . \bibitem[Bahnemann ()]{b2}\label{b2} ‘Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production’. H G Bahnemann . \textit{Arch Virol} 1975. 47 p. . \bibitem[Gubbins et al. ()]{b8}\label{b8} ‘CD4+ T-cell responses to foot-and-mouth disease virus in vaccinated cattle’. C Gubbins , S Prentice , H Juleff , N D Charleston , B . \textit{J. Gen Virol} 2013. 94 p. . (Pt 1) \bibitem[Green et al. ()]{b27}\label{b27} ‘Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults’. C A Green , E Scarselli , C J Sande , A J Thompson , C M De Lara , K S Taylor , K Haworth , Del Sorbo , M , Angus B Siani , L , Di Marco , S Traboni , C Folgori , A Colloca , S Capone , S Vitelli , A Cortese , R Klenerman , P Nicosia , A Pollard , AJ . \textit{Sci Trasl Med} 2015. p. 12. \bibitem[Selim et al. ()]{b45}\label{b45} ‘Comparative Study for Immune Efficacy of Two Different Adjuvants Bivalent FMD Vaccines in Sheep’. A M A Selim , N Z Abouzeid , A M Aggour , N M Sobhy . \textit{Journal of American Science} 2010. 6 (10) p. . \bibitem[Childerstone et al. ()]{b11}\label{b11} ‘Demonstration of bovine CD8+ T-cell responses to foot-and-mouth disease virus’. A J Childerstone , L Cedillo-Baron , M Foster-Cuevas , R M Parkhouse . \textit{J Gen Virol} 1999. 80 p. . (Pt 3) \bibitem[Moonen et al. ()]{b37}\label{b37} ‘Detection of carriers of foot-and-mouth disease virus among vaccinated cattle’. P Moonen , L Jacob , Crienenma , A Dekker . \textit{Vet Microbiol} 2004. 15 (3-4) p. . \bibitem[Grubman ()]{b28}\label{b28} ‘Development of novel strategies to control foot-and mouth disease marker vaccines and antivirals’. M J Grubman . \textit{Biologicals} 2005. 33 p. . \bibitem[Ilott et al. ()]{b32}\label{b32} ‘Dexamethasone inhibits virus production and the secretory IgA response in oesophageal-pharyngeal fluid in cattle persistently infected with foot-andmouth disease virus’. M C Ilott , J S Salt , R M Gaskell , R P Kitching . \textit{Epidemiol Infect} 1997. 118 p. . \bibitem[Ebeid et al. ()]{b23}\label{b23} ‘Emergency vaccination of cattle against foot-and-mouth disease confers complete clinical protection in 7 days and partial protection in 4 days’. M Ebeid , F K Hamouda , M Farag , S E Mahdy . \textit{4th Sci. Conf., Al-Kasr 25-28 Fac}, (Egypt) 2011. Benha University \bibitem[Cubillos et al. ()]{b13}\label{b13} ‘Enhanced mucosal immunoglobulin A response and solid protection against foot-andmouth disease virus challenge induced by a novel dendrimeric peptide’. C Cubillos , B G De La Torre , A Jakab , G Clementi , E Borras , J Barcena , D Andreu , F Sobrino , E Blanco . \textit{Journal of Virology} 2008. 82 p. . \bibitem[Voller et al. ()]{b50}\label{b50} ‘Enzyme immune assay in diagnostic medicine, theory and practice’. A Voller , D E Bidwell , Ann Bartlett . \textit{Bull. World Health Org} 1976. 53 p. . \bibitem[Iyer et al. ()]{b33}\label{b33} ‘Evaluation of three ready to formulate oil adjuvants for foot and mouth disease vaccine production’. A V Iyer , S Ghosh , S N Singh , R A Deshmukh . \textit{Vaccine} 2000. 19 (9) p. . \bibitem[Barnett et al. ()]{b4}\label{b4} ‘Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the "carrier" state in sheep’. P V Barnett , P Keel , S Reid , R M Armstrong , R J Statham , C Voyce , N Aggarwal , S J Cox . \textit{Vaccine} 2004. 12 (9) p. . \bibitem[Cox and Barnett ()]{b12}\label{b12} ‘Experimental evaluation of foot-and mouth disease vaccines for emergency use inruminants and pigs’. S J Cox , P V Barnett . \textit{Vet. Res. Vet} 2009. 40 (3) p. 13. \bibitem[Fao (2012)]{b25}\label{b25} ‘Foot-and-mouth disease caused by serotype SAT2 in Egypt and Libya: A regional concern for animal health in North Africa and the Middle East’. Fao . \textit{EMPRES WATCH} 2012. March 2012. 25. \bibitem[Bucafusco et al. ()]{b5}\label{b5} ‘Foot-and-mouth disease vaccination induces cross-reactive IFN-? responses in cattle that are dependent on the integrity of the 140S particles’. D Bucafusco , Di Giacomo , S Pega , J Schammas , J M Cardoso , N Capozzo , A V Perez-Filgueira , M . \textit{Virology} 2015. 476 p. . \bibitem[Alexandersen and Mowat ()]{b1}\label{b1} ‘Foot-and-mouth disease: host range and pathogenesis’. S Alexandersen , N Mowat . \textit{And persistent infection Plos One} 2005. 2012. 288 (9) p. e44365. (Curr. Top. Microbiol. Immunol.) \bibitem[Hr and Graves (1963)]{b14}\label{b14} ‘Formalin-Treated Foot-and-Mouth Disease Virus: Comparison of Two Adjuvants in Cattle’. Cunliffe Hr , J H Graves . \textit{Can J Comp Med Vet Sci} 1963. 1963 Aug. 27 (8) p. . \bibitem[Gurung et al. ()]{b29}\label{b29} R B Gurung , A C Purdie , R J Whittington , D J Begg . \textit{Cellular and humoral immune responses in sheep vaccinated with candidate antigens MAP2698c and MAP3567 from Mycobacterium avium subspecies paratuberculosis}, 2014. \bibitem[Wael Mossad Gamal El-Din, Ehab El-Sayed Ibrahim*, Hind Daoud and Samir Mohamed Ali ()]{b51}\label{b51} ‘Humeral and cellular immune response of Egyptian trivalent foot and mouth disease oil vaccine in sheep’. \textit{Res. Opin. Anim. Vet. Sci} Wael Mossad Gamal El-Din, Ehab El-Sayed Ibrahim*, Hind Daoud and Samir Mohamed Ali (ed.) 2014. 2014. 4 (4) p. . \bibitem[Habjanec et al. ()]{b30}\label{b30} ‘Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer’. L Habjanec , B Halassy , J Tomasi? . \textit{Int Immunopharmacol} 2008. 8 (5) p. . \bibitem[Delcenserie et al. ()]{b17}\label{b17} ‘Immunomodulatory effects of probiotics in the intestinal tract’. V Delcenserie , D Martel , M Lamoureux , J Amiot , Y Boutin , RoyD . \textit{Curr Issues Mol Biol} 2008. 10 (1-2) p. . \bibitem[Diaz-San et al. ()]{b19}\label{b19} \textit{Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by}, Diaz-San , F Segundo , T Rodriguez-Calvo , A Avila , N Sevilla . IL-10. 2009. \bibitem[Summerfield et al. ()]{b48}\label{b48} ‘Innate immune responses against foot-and-mouth disease virus: current understanding and future directions’. A Summerfield , L Guzylack-Piriou , L Harwood , K C Mccullough . \textit{Vet Immunol Immunopathol} 2009. 128 p. . \bibitem[Oh et al. ()]{b38}\label{b38} ‘Interferon-? induced by in vitro re-stimulation of CD4+ T-cells correlates within vivoFMD vaccine induced protection of cattle against disease Osama’. Y Oh , L Fleming , B Statham , P Hamblin , P Barnett , D J Paton , J H Park , Y S Joo , S Parida . \textit{Studies on inactivated Foot and Mouth Disease virus vaccine}, 2012. 1992. \bibitem[ MJ ()]{b21}\label{b21} ‘Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression’. MJ . \textit{J. Virol} 2010. 84 (4) p. . \bibitem[Parida et al. ()]{b39}\label{b39} ‘Interferongamma production in vitro from whole blood of footand-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV’. S Parida , Y Oh , S M Reid , S J Cox , R J Statham , M Mahapatra , J Anderson , P V Barnett , B Charleston , D J Paton . \textit{Vaccine} 2006. 13 (7) p. . \bibitem[Vilcek and Sen (ed.) ()]{b49}\label{b49} \textit{Interferons and other cytokines}, J Vilcek , G C Sen . Fields Virology Philadelphia, PA. (ed.) 1996. p. . VMVSc Thesis (Virology), University of Cairo \bibitem[ISA 206 used in trivalent FMD vaccine Vet. World]{b24}\label{b24} ‘ISA 206 used in trivalent FMD vaccine’. \textit{Vet. World} 201. (ISA. under press) \bibitem[Seppic ()]{b46}\label{b46} \textit{Montanide ISA 201 VG-ready to use oil adjuvant for veterinary vaccines}, Seppic . 2008. Paris: Seppic. (Tech Bull) \bibitem[Montanide ISA? 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle Vaccine (2013)]{b16}\label{b16} ‘Montanide ISA? 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle’. \textit{Vaccine} 2013 Jul 18. \bibitem[Deville et al. ()]{b44}\label{b44} \textit{MontanideTM adjuvants for stimulation of cellular immune response in FMD vaccines Tech Bull}, Sébastien Deville , Juliette Ben Arous , François Bertrand , Laurent Dupuis . 2013. Paris: Seppic. \bibitem[Bahnemann and Mesquita ()]{b3}\label{b3} ‘Oiladjuvant vaccine against foot-and-mouth disease’. H G Bahnemann , J A Mesquita . \textit{Boletin del Centro Panamericano Fiebre Aftosa} 1987. 53 p. . \bibitem[Macpherson and Stocher ()]{b36}\label{b36} ‘Polyma transformation hamster cell clones, an investigation of genetic factors affecting cell competence’. M Macpherson , B Stocher . \textit{Virology} 1962. 16 p. . \bibitem[Ferreira ()]{b26}\label{b26} ‘Prubade microneutralization poraestudies de anticueropos de la fibrea fsta 13 th Centropanamericano Fiebre Aftosa’. M E V Ferreira . \textit{Front Cell Infect Microbiol} 1976. 16 (21/22) p. 93. \bibitem[Zhang et al. ()]{b54}\label{b54} ‘Rapeseed oil and ginseng saponins work synergistically to enhance Th1 and Th2 immune responses induced by the foot-and-mouth disease vaccine’. C Zhang , Y Wang , M Wang , X Su , Y Lu , F Su , S Hu . \textit{Clin Vaccine Immunol} 2014. 21 (8) p. . \bibitem[Wilkins and Gale ()]{b52}\label{b52} ‘Recognition of viruses by cytoplasmic sensors’. C Wilkins , M GaleJr . \textit{Curr Opin Immunol} 2010. 22 p. . \bibitem[Vr ()]{b10}\label{b10} ‘Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development ofPulmonary Tuberculosis’. JC , Pereira Vr . \textit{Pulm Med} 2012. 2012. 2012 p. 745483. \bibitem[Li et al. ()]{b22}\label{b22} ‘The comparison of the efficacy of swine FMD vaccine emulsified with oil adjuvant of ISA 201 VG or ISA 206 VG’. Dong Li , Chunxue Zhou , Daliang She , Pinghua Li , Pu Sun , Xingwen Bai , Yingli Chen , Baoxia Xie , Zaixin Liu . \textit{Journal of Biosciences and Medicines} 2013. 2013. 1 p. . \bibitem[Rothel et al. (1992)]{b41}\label{b41} ‘The gamma-interferon assay for diagnosis of bovine tuberculosis in cattle: conditions affecting the production of gamma-interferon in whole blood culture’. J S Rothel , S L Jones , L A Corner , J C Cox , P R Wood . \textit{Aust Vet J} 1992. 1992 Jan. 69 (1) p. . \bibitem[Santos De Los et al. ()]{b43}\label{b43} ‘The leader proteinase of foot-andmouth disease virus inhibits the induction of beta interferon mRNA and blocks the host innate immune response’. T Santos De Los , B S De Avila , R Weiblen , M J Grubman . \textit{J Virol} 2006. 2006. 80 p. . \bibitem[Phillips and Dinter ()]{b40}\label{b40} ‘The role of interferon in persistent infection with foot-and mouth disease virus’. L Phillips , Z Dinter . \textit{J Gen Microbiol} 1963. 32 p. . \bibitem[Depa et al. ()]{b18}\label{b18} ‘Update on epidemiology and control of foot and mouth disease -A menace to international trade and global animal enterprise’. P M Depa , U Dimri , M C Sharma , R Tiwari . \textit{Vet. World} 2012. 5 (11) p. . \bibitem[Killington et al. ()]{b34}\label{b34} ‘Virus purification’. R A Killington , A Stokes , J C Hierholzer . \textit{Virology Methods Manual}, B W J O Mahy \& H, Kangro (ed.) (New York) 1996. Academic Press. p. . \end{bibitemlist} \end{document}